The global market for Electronic Nose estimated at US$19 Million in the year 2022, is projected to reach a revised size of US$47.1 Million by 2030, growing at a CAGR of 12% over the analysis period 2022-2030.
Environmental Monitoring, one of the segments analyzed in the report, is projected to record a 12.7% CAGR and reach US$20.2 Million by the end of the analysis period.
Taking into account the ongoing post pandemic recovery, growth in the Food & Beverage segment is readjusted to a revised 11.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $5.6 Million, While China is Forecast to Grow at 11.1% CAGR
The Electronic Nose market in the U.S. is estimated at US$5.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 10.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.
Select Competitors (Total 36 Featured) -
AIRSENSE Analytics GmbH
Alpha MOS
Aryballe Technologies
Enose Company
Foodsniffer (FKA PERES) / ARS Labs
Intelesens (FKA ST&D)
MYDX
Odotech
Olfaguard
Plasmion GmbH
Roboscientific
Sensigent
Sensing Dynamics
Shenzhen Beautymate Technology Co., Ltd.
Stratuscent
Tellspec
The eNose Company
Vaporsens
What`s New for 2023?
Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...